Comparative efficacy of targeted therapies and immunotherapy in advanced non-small cell lung cancer: a systematic review
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242275Keywords:
Non-small cell lung cancer, Targeted therapy, Immunotherapy, PD-1 inhibitors, Combined chemotherapy protocols, Treatment outcomes, Meta-analysisAbstract
Targeted therapies and immunotherapies revolutionized advanced NSCLC treatment and outcomes. Targeted therapies exploit specific genetic mutations (e.g., EGFR, ALK, BRAF) to inhibit cancer growth while offering significant benefits in progression-free and overall survival. Targeted therapy drugs for advanced NSCLC include osimertinib, gefitinib, erlotinib, alectinib, brigatinib, lorlatinib, ceritinib, dabrafenib, trametinib, and crizotinib.Resistance and side effects like ILD and hepatotoxicity and cardiovascular issues remain challenges. Immunotherapies with checkpoint inhibitors PD-1, PD-L1, CTLA-4 enhance the immune system's ability and body becomes able to combat cancer. Drugs like pembrolizumab, nivolumab, and atezolizumab have shown good efficacy but immune-related adverse effects remain a significant concern. Combination therapies such as e.g., nivolumab and ipilimumab can be a better option which can be concerned because these therapies also show promise in enhancing treatment outcomes.
References
Non-Small cell lung cancer. Yale Medicine. 2022. Available at: https://www.yalemedicine.org/conditions/non-small-cell-lung-cancer. Accessed on 12 June 2024.
De Jong D, Das JP, Ma H, Valiplackal JP, Prendergast C, Roa T, et al. Novel targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer. Cancers. 2023;15(10):2855.
Spagnolo CC, Ciappina G, Giovannetti E, Squeri A, Granata B, Lazzari C, et al. Targeting MET in Non-Small Cell Lung Cancer (NSCLC): a new old story? Int J Mol Sci. 2023;24(12):10119.
Pretelli G, Spagnolo CC, Ciappina G, Santarpia M, Pasello G. Overview on therapeutic options in uncommon EGFR mutant non-small cell lung cancer (NSCLC): new lights for an unmet medical need. Int J Mol Sci. 2023;24(10):8878.
Peng Y, Zhao Q, Liao Z, Ma Y, Ma D. Efficacy and safety of first‐line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta‐analysis. Cancer. 2023;129(8):1261-75.
Nelson TA, Wang N. Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease. Transl Lung Cancer Res. 2023;12(2):379.
Kumar S, Chatterjee M, Ghosh P, Ganguly KK, Basu M, Ghosh MK. Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients. Genes Dis. 2023;10(4):1318-50.
Ortega MA, Boaru DL, De Leon-Oliva D, Fraile-Martinez O, García-Montero C, Rios L, et al. PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications. J Mol Med. 2024;27:1-4.
Liu N, Zhang R, Shi Q, Jiang H, Zhou Q. Intelligent delivery system targeting PD-1/PD-L1 pathway for cancer immunotherapy. Bioorg Chem. 2023;136:106550.
Wu Y, Yu G, Jin K, Qian J. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies. Front Immunol. 2024;15:1349502.
Parvez A, Choudhary F, Mudgal P, Khan R, Qureshi KA, Farooqi H, et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front Immunol. 2023;14:1296341.
Cheng Y, Zhang T, Xu Q. Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm. 2021;2(4):692-729.
Guo H, Zhang J, Qin C, Yan H, Liu T, Hu H, et al. Biomarker-targeted therapies in non–small cell lung cancer: current status and perspectives. Cells. 2022;11(20):3200.
Liu WJ, Du Y, Wen R, Yang M, Xu J. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol Ther. 2020;206:107438.
Malik P, Rani R, Solanki R, Patel VH, Mukherjee TK. Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies. Explor Target Antitumor Ther. 2023;4(5):850.
Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36.
Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023;23(1):162.
Safa SH, Faramarzi F, Khorasani S, Alimohammadi M, Tahmasebi S, Akhavan Sigari R. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023;23:162.
Carlisle JW, Ramalingam SS. Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncol. 2019;15(8):805-16.
Köhler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie. 2013;36(9):510-8.
Chuang CH, Chen HL, Chang HM, Tsai YC, Wu KL, Chen IH, et al. Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-naïve ALK-positive lung cancer. Cancers. 2021;13(8):1966.
Naito T, Shiraishi H, Fujiwara Y. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases. Jpn J Clin Oncol. 2021;51(1):37-44.
Samacá-Samacá D, Prieto-Pinto L, Peréz AY, Valderrama C, Hernández F. Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis. Lung Cancer Manag. 2023;12(2):LMT59.
Tsamis I, Gomatou G, Chachali SP, Trontzas IP, Patriarcheas V, Panagiotou E, et al. BRAF/MEK inhibition in NSCLC: Mechanisms of resistance and how to overcome it. Clin Transl Oncol. 2023;25(1):10-20.
Gouda MA, Subbiah V. Expanding the benefit: Dabrafenib/Trametinib as tissue-agnostic therapy for BRAF V600E–positive adult and pediatric solid tumors. Am Soc Clin Oncol Educ Book. 2023;43:e404770.
Li Y, Lv Y, Zhang C, Fu B, Liu Y, Hu J. Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy. Eur J Med Chem. 2023;257:115477.
Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nat Rev Clin Oncol. 2023;20(3):143-59.
Reck M, Popat S, Grohé C, Corral J, Novello S, Gottfried M, et al. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. Lung Cancer. 2023;179:107173.
Zabeti Touchaei A, Vahidi S. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways. Cancer Cell Int. 2024;24(1):102.
Azimnasab-Sorkhabi P, Soltani-Asl M, Kfoury Junior JR. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells. Hum Cell. 2023;36(4):1225-32.
Ren L. The Role of Pembrolizumab (Keytruda) in Treating Non-small Cell Lung Cancer. Highlights Sci Eng Technol. 2023;36:608-13.
Paz-Ares L, Horn L, Borghaei H, Spigel DR, Steins M, Ready N, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(18):LBA109.
Molina-Vila MA, Stahel R, Dafni U, Boulter C, Wirth R, Crowther H, et al. Interlaboratory performance of the oncomine comprehensive assay v3. J Clin Pathol. 2023;76(7):409-17.
Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18(5):1472-82.
McGranahan N, Furness AJ, Rosenthal R, Ramsden AJ, Wilson GA, Birkbak NJ, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463-9.
Davies J, Bernicker EH. ALK rearrangement and its role in non-small cell lung cancer. BMJ Oncol. 2023;8(2):298-310.
Park CK, Cho H, Kim KH. Molecular characteristics and clinical outcomes of ROS1-positive non-small cell lung cancer: a review. Ther Adv Med Oncol. 2023;15:17588359231182905.
MacMahon C, Maher MM. A narrative review of the history, current status, and future prospects of EGFR-targeted therapies in non-small cell lung cancer (NSCLC). Curr Oncol. 2023;30(6):5432-48.
Jacobson JO, Govindan R. Systemic Therapy for Non-Small Cell Lung Cancer: Past, Present, and Future. J Clin Oncol. 2023;41(29):3090-100.
Rolfo C, Ruiz R, O’Hara M, Gil-Bazo I, Brose MS, Bronte G, et al. Molecular and immune biomarkers for small cell lung cancer: Implications for therapy. J Thorac Oncol. 2023;18(5):632-45.
Nishino M, Hatabu H, Johnson BE, McLoud TC. State of the art: Response assessment in lung cancer in the era of genomic medicine. Radiology. 2014;273(1):21-38.
Pai-Scherf LH, Blumenthal GM, Li H, Yuan W, Zhao H, Duan J, et al. FDA approval summary: Pembrolizumab for treatment of metastatic non‐small cell lung cancer: first-line therapy and beyond. Oncologist. 2017;22(11):1392-9.
Xu L, Yang Y, Ling Y, Cao J, Li L, Zhao H, et al. Clinical application of ctDNA in non-small cell lung cancer. Front Oncol. 2022;12:989401.
Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57.
Siemann DW, Rojiani AM. Anti-angiogenic therapies in non-small cell lung cancer: The potential role of vasculature-targeted therapies. Clin Transl Oncol. 2022;24(9):1661-71.
Cho BC, Park K, Tan EH, Cho EK, Min YJ, Yi JH, et al. A phase II trial of ramucirumab and pembrolizumab as first-line treatment for advanced non-small cell lung cancer: outcomes and implications. Thorac Cancer. 2023;14(5):533-42.
Zhang Y, Sun Z, Xiao X, Bai H, Wang X. Genetic testing and applications in the personalized treatment of non-small cell lung cancer (NSCLC). Ther Adv Med Oncol. 2023;15:17588359231182902.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinò L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-94.
Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866-74.
Wu YL, Lu S, Lu Y, Zhou C, Shi Y, Kondo M, et al. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer. J Thorac Oncol. 2018;13(10):1539-48.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Eng J Med. 2011;364(26):2507-16.
Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007;109(11):2171-81.
Motzer RJ, Escudier B, Gannon A, Figlin RA. Sunitinib: ten years of successful clinical use and study in advanced renal cell carcinoma. The Oncologist. 2017;22(1):41-52.
Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. InSeminars Oncol WB Saunders. 2005;32(1):61-8.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med. 2008;359(4):378-90.
McArthur GA. Combination therapies to inhibit the RAF/MEK/ERK pathway in melanoma: we are not done yet. Frontiers Oncol. 2015 ;5:161.
Engelman JA, Jänne PA. Factors predicting response to EGFR tyrosine kinase inhibitors. InSeminars in respiratory and critical care medicine 2005;26(3):314-22.
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med. 2006;355(23):2408-17.
